TRANEXAMIC ACID | N022430 | AMRING PHARMACEUTICALS INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| NVD | 2012-11-09 | Terminated 2015-06-11 | — | |
Ferring B.V. v. Watson Pharmaceuticals, Inc. Florida, et al 1 patentANDA 202093tranexamic acid | NVD | 2011-11-25 | Terminated 2015-06-11 | — |
| NVD | 2011-07-08 | Terminated 2014-03-24 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Appco Pharma LLC FDA-2026-P-5578 Appco Pharma LLC submitted this suitability petition under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act and 21 CFR 314.93, requesting FDA approval to file an ANDA for Tranexamic Acid Tablets, USP 1300 mg, which differs in strength from the reference listed drug LYSTEDA (Tranexami | Suitability | 2026-05-14 | Open | Appco Pharma LLC |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.